121 related articles for article (PubMed ID: 10181679)
1. The Pharmaceutical Benefits Scheme and the shifting paradigm of welfare policy.
Löfgren H
Aust Health Rev; 1998; 21(2):111-23. PubMed ID: 10181679
[TBL] [Abstract][Full Text] [Related]
2. Challenges and opportunities for the Pharmaceutical Benefits Scheme.
Clarke PM
Med J Aust; 2012 Feb; 196(3):153-4. PubMed ID: 22339510
[No Abstract] [Full Text] [Related]
3. "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency.
Davis P
Aust Health Rev; 2004 Nov; 28(2):171-81. PubMed ID: 15527397
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals in Australia: developments in regulation and governance.
Lofgren H; Boer Rd
Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical benefits scheme policy: confused and tough on patients.
Doran E; Henry D
Intern Med J; 2006 Apr; 36(4):211-3. PubMed ID: 16640735
[No Abstract] [Full Text] [Related]
6. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
Clarke PM
Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
[No Abstract] [Full Text] [Related]
7. PBS medications--improving access for Aboriginal and Torres Strait Islander peoples.
Couzos S
Aust Fam Physician; 2005 Oct; 34(10):841-4. PubMed ID: 16217569
[TBL] [Abstract][Full Text] [Related]
8. Drug policy down under: Australia's pharmaceutical benefits scheme.
Duckett SJ
Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
[TBL] [Abstract][Full Text] [Related]
9. PBS reform - a missed opportunity?
de Boer R
Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
[TBL] [Abstract][Full Text] [Related]
10. Interest groups and state Medicaid drug programs.
Pracht EE; Moore WJ
J Health Polit Policy Law; 2003 Feb; 28(1):9-39. PubMed ID: 12705416
[TBL] [Abstract][Full Text] [Related]
11. When success sours: PBMs under scrutiny.
Carroll J
Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
[No Abstract] [Full Text] [Related]
12. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
13. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Robertson J; Walkom EJ; Henry DA
Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
[TBL] [Abstract][Full Text] [Related]
14. Managing psychotropic drug costs: will formularies work?
Huskamp HA
Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Lopert R
Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
[TBL] [Abstract][Full Text] [Related]
16. The economic crisis, the Pharmaceutical Benefits Scheme, and the dilemmas of medicines policy.
Löfgren H
Aust Health Rev; 2009 May; 33(2):171-5. PubMed ID: 19563305
[No Abstract] [Full Text] [Related]
17. The Pharmaceutical Benefits Scheme.
Med J Aust; 1988 Oct; 149(7):394-6. PubMed ID: 3173200
[No Abstract] [Full Text] [Related]
18. Incentives in the Medicare prescription drug benefit.
Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
[No Abstract] [Full Text] [Related]
19. Are Australia's drugs too cheap for our own good?
Hindle D
Aust Health Rev; 2001; 24(2):4-6. PubMed ID: 11496469
[No Abstract] [Full Text] [Related]
20. Politicians', bureaucrats' drug plans deemed too costly for public formularies.
Kondro W
CMAJ; 2007 Mar; 176(6):755. PubMed ID: 17353524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
